Biocom California’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom California has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Close
Senior Vice President and Chief Scientific Officer, Emerging Science and Innovation (ES&I), Pfizer Worldwide Research, Development, and Medical
Uwe Schoenbeck leads Pfizer’s Emerging Science & Innovation (ES&I) team. Part of Worldwide Research, Development & Medical, ES&I is charged with enhancing Pfizer’s pipeline through translation of external emerging science into breakthrough therapies for patients. Through the dedicated outreach to academia, consortia and Biotech via its Emerging Science Liaisons located around the globe ES&I works across Pfizer’s Therapeutic Areas to harnesses external cutting edge preclinical assets and breakthrough technologies applying a broad range of partnering vehicles, including research collaborations, consortia, licensing, acquisitions. With its Pfizer Innovation team ES&I also engages in equity investments as well as Seed investments and formation of new companies. Its Target Science team is focused on novel target and biology discovery research to introduce differentiated First-in-Class programs with enhanced confidence in rationale into the WRD portfolio. And through its Centers for Therapeutic Innovation (CTI) ES&I prosecutes cutting edge science sourced from leading academic and medical centers globally, working in close partnership with external PIs and building an exciting pipeline across the range of Pfizer’s core areas. This end-to-end innovation capability aims to strengthen Pfizer’s research engine and provide key drivers for a pipeline of truly differentiated first-in-class assets as well as breakthrough technologies by effectively combining external innovation with internal drug development capabilities.
Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team. Prior to joining the company, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position at Brigham & Women’s Hospital, Harvard Medical School. He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in molecular & cell biology, cardiovascular research, immunology, and metabolism.